1. Home
  2. LNSR vs SAVA Comparison

LNSR vs SAVA Comparison

Compare LNSR & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$11.45

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.12

Market Cap

156.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNSR
SAVA
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Electronics
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
156.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LNSR
SAVA
Price
$11.45
$2.12
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$15.00
$5.00
AVG Volume (30 Days)
44.5K
993.1K
Earning Date
02-26-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,141,000.00
N/A
Revenue This Year
$19.55
N/A
Revenue Next Year
$35.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.02
N/A
52 Week Low
$7.25
$1.15
52 Week High
$17.31
$4.98

Technical Indicators

Market Signals
Indicator
LNSR
SAVA
Relative Strength Index (RSI) 47.37 36.39
Support Level $11.19 $1.96
Resistance Level $11.81 $2.16
Average True Range (ATR) 0.31 0.16
MACD -0.08 -0.03
Stochastic Oscillator 18.61 16.83

Price Performance

Historical Comparison
LNSR
SAVA

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: